Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Area of Science:

• Immunology
• Biotechnology
• Pharmacology

Background:

• Targeting the PD-1/PD-L1 interaction is a key strategy in cancer immunotherapy.
• Efficient screening platforms are crucial for developing effective PD-1/PD-L1 inhibitors.
• Previous SPR-based assays showed promise but required optimization for large-scale screening.

Purpose of the Study:

• To develop an optimized, second-generation Surface Plasmon Resonance (SPR) screening platform for PD-1/PD-L1 inhibitors.
• To improve PD-1 orientation control and reduce protein consumption compared to the first-generation platform.
• To validate the reliability and high-throughput capabilities of the enhanced SPR assay for identifying novel cancer immunotherapy agents.

Main Methods:

• Development of a second-generation PD-1/PD-L1 inhibitor SPR screening platform.
• Implementation of a dual-step coupling process (amine and bio-streptavidin) for enhanced PD-1 orientation.
• Validation of the optimized platform using the PD-1/PD-L1 inhibitor BMS-1166 and comparison with ELISA.

Main Results:

• The optimized SPR platform demonstrated enhanced control over PD-1 orientation on the chip.
• The assay successfully validated with BMS-1166, showing comparable blockade effects to previous methods.
• The optimized platform confirmed reliability and efficiency, reducing PD-1 protein consumption.

Conclusions:

• The second-generation SPR screening platform is a reliable and high-throughput tool for evaluating PD-1/PD-L1 inhibitors.
• This optimized assay advances cancer immunotherapy research by facilitating the discovery of novel immune checkpoint inhibitors.
• SPR technology holds significant potential for screening immune checkpoint inhibitors.